|
Market Closed -
NYSE
21:00:00 18/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 3.210 USD | -0.31% |
|
+0.94% | +16.73% |
| 11:16am | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 08-14 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 366.4 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 79.24% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 199.9 | 135.6 | 203.9 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 226.27% | -32.17% | 50.41% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -3.13x | -2.9x | -3.07x |
| PBR | - | - | - | 0.78x | 0.99x | 1.55x | 1.5x | 1.74x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -0.36x | 0.55x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 1,092x | 925x | 27.3x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 596x | 342x | 15.2x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.6x | -0.98x | -1.41x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.63x | -0.94x | -1.4x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.8x | -0.93x | -1.32x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -55.6% | -108% | -75.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.025 | -1.107 | -1.044 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.3355 | 0.3962 | 13.44 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -124.5 | -139 | -144.5 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -122.8 | -143.7 | -145.4 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -115.2 | -137 | -138.6 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -166.6 | -230.9 | -162.5 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 3.210 | 3.210 | 3.210 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,152 | - | - |
| Announcement Date | 21/09/21 | 01/05/23 | 28/03/24 | 26/03/25 | 16/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.13x | 595.82x | -1.6x | -.--% | 366M | |
| 33.23x | 5.94x | 17.65x | 0.97% | 48.63B | |
| -22.42x | 307.68x | -22.84x | -.--% | 46.3B | |
| 48.36x | 5.61x | 30.68x | -.--% | 41.97B | |
| 30.91x | 3.06x | 13.22x | -.--% | 39.51B | |
| 29.75x | 8.57x | 21.59x | 0.39% | 31.75B | |
| 33.57x | 5.5x | 24.97x | -.--% | 16.48B | |
| 23.22x | 2.04x | 8.81x | 1.16% | 14B | |
| 74.7x | 3.95x | 15.31x | -.--% | 13.33B | |
| Average | 27.58x | 104.24x | 11.98x | 0.28% | 28.04B | |
| Weighted average by Cap. | 26.34x | 61.63x | 12.03x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
